SCHEMBL3905178

SCHEMBL3905178

CN(C)C(C)(C)C(NC(=O)c1cc(F)c(Cl)cc1Cl)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
APEX1 P27695 1/20 0.42
GPR27 Q9NS67 1/20 0.42
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
MAPT P10636 1/20 0.38
TACR3 P29371 1/20 0.37
ITGB3 P05106 2/20 0.37
ITGA2B P08514 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP2C19 P33261 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 1/20 0.36
GPR139 Q6DWJ6 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903988 0.86 CTSL (0.44) LMNAKMT2AITGB3ITGA2BHPGD
SCHEMBL3905283 0.83 MEN1 (0.49) POLBGPR27KMT2ANPC1RAB9A
SCHEMBL3901053 0.83 GPR139 (0.49) POLBLMNAKMT2ANPC1RAB9A
SCHEMBL3902148 0.82 LMNA (0.44) POLBLMNAKMT2ARAB9AMAPT
SCHEMBL3910586 0.82 CRHR1 (0.46) POLBLMNAKMT2AMAPTSMN1; SMN2
SCHEMBL3907125 0.80 TAS1R3 (0.51) LMNANPC1RAB9ASMN1; SMN2GPR139
SCHEMBL3902992 0.80 TYK2 (0.45) POLBLMNAKMT2ANPC1RAB9A
SCHEMBL3905781 0.79 UTS2R (0.50) LMNAKMT2ANPC1RAB9AMAPT
SCHEMBL3903980 0.79 MEN1 (0.42) POLBLMNAKMT2ATACR3SMN1; SMN2
SCHEMBL3901504 0.78 LMNA (0.43) LMNASMN1; SMN2ALDH1A1GPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 POLB 3051/4885APEX1 4551/4885GPR27 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.